Table 1.
Clinical summary of the COVID-19 patients highlighting clinical parameters across recovered and mortality.
| Groups | Total (n = 246) | Mortality (n = 18) | Recovered (n = 228) | p-value |
|---|---|---|---|---|
| Gender F|M | 79|166 | 3|14* | 76|152 | 0.18 b |
| Age | 48 (30–63) | 63 (55–68) | 46 (30–63) | <0.001 a |
| Respiratory Support | 83 (33.73%) | 18 (100%) | 65 (28.50%) | – |
| E gene | 24.19 (21.21–27.51) | 22.48 (19.62–27.69) | 24.34 (21.56–27.51) | 0.21 a |
| RdRp gene | 25.11 (21.51–28.91) | 23.67 (20.59–28) | 25.24 (21.57–28.94) | 0.26 a |
| Symptoms | ||||
| Shortness of Breath | 82 (33.33%) | 10 (55.56%) | 72 (31.57%) | 0.037 b |
| Fever | 174 (70.73%) | 10 (55.56%) | 164 (71.92%) | 0.141 b |
| Sore Throat | 132 (53.65%) | 6 (33.33%) | 126 (55.26%) | 0.72 b |
| Body ache | 47 (19.10%) | 4 (22.22%) | 43 (18.85%) | 0.72 b |
| Abdominal pain | 4 (1.62%) | 3 (16.67%) | 1 (0.43%) | <0.001 b |
| Nausea | 18 (7.31%) | 2 (11.11%) | 16 (7.01%) | 0.52 b |
| Headache | 20 (8.13%) | 1 (5.56%) | 19 (8.33%) | 0.64 b |
| General weakness | 28 (11.38%) | 0 (0) | 28 (12.28%) | – |
| No Co-morbidities | 141 (57.31%) | 4 (22.22%) | 137 (60.08%) | <0.001 b |
| Comorbidities | 105 (42.68%) | 14 (77.77%) | 91 (39.92%) | |
| Diabetes | 62 (25.20%) | 8 (44.44%) | 54 (23.68%) | 0.05 b |
| Hypertension | 74 (30.08%) | 12 (66.66%) | 62 (27.19%) | <0.001 b |
| Hypothyroidism | 14 (5.69%) | 4 (22.22%) | 10 (4.38%) | <0.001 b |
| Asthma | 4 (1.62%) | 0 (0%) | 4 (1.75%) | – |
| Hospital stay | 11 (5–14) | 13 (6–18) | 11 (5–14) | 0.34 a |
Data are shown as median [interquartile range (IQR)] or n (%).
a
Kruskal–Wallis test.
b
Chi-square test.
*Missing data.
Values of significance are highlighted in bold.